Combining Ceraxa and Vinblastine to treat difficult cases of Acute Myeloid Leukemia
Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This study is looking at how well a new treatment called Ceraxa works with Vinblastine for people with relapsed or hard-to-treat Acute Myeloid Leukemia (AML), to find the best dose and help fight cancer cells while keeping side effects low.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Keystone Nano, INC. NIH-funded |
| Lab location | 1 site (State College, UNITED STATES) |
| Project ID | NIH-10704116 on NIH RePORTER |
What this research studies
This research investigates the use of Ceraxa, a ceramide nanoliposome, in combination with Vinblastine for patients suffering from relapsed or refractory Acute Myeloid Leukemia (AML). The study aims to determine the optimal dosage of Ceraxa and assess its effectiveness both alone and alongside Vinblastine. By targeting dysfunctional sphingolipid metabolism, the treatment seeks to induce cell death in cancer cells while minimizing adverse effects. Patients will be monitored for safety and efficacy as part of this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with relapsed or refractory Acute Myeloid Leukemia.
Not a fit: Patients who are not diagnosed with Acute Myeloid Leukemia or those who are not experiencing relapse or refractory cases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves outcomes for patients with difficult-to-treat AML.
How similar studies have performed: Previous studies have shown promising results with similar approaches, particularly in solid tumors, indicating potential for success in AML.
Where this research is happening
State College, UNITED STATES
- Keystone Nano, INC. — State College, United States (Active)
Researchers
- Principal investigator: Adair, Bernadette Mcmahon — Keystone Nano, INC.
- Study coordinator: Adair, Bernadette Mcmahon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.